Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies.

P Kralickova,V Thon,P Zak,J Krejsek,J Kuhnova,M Simkovic,O Soucek,P Vodarek,C Andrys,M Motyckova,L Smolej,E Mala

doi:10.1155/2017/7304658

Abstract

Humoral deficiencies represent a broad group of disorders. The aim of the study was to compare the levels of antibodies against pneumococcal capsular polysaccharides (anti-PCP) and natural anti-galactosyl (anti-Gal) antibodies in (1) patients with chronic lymphocytic leukaemia (CLL), (2) patients with common variable immunodeficiency (CVID), and (3) a healthy population and to explore their diagnostic and prognostic potential. Serum immunoglobulin levels and levels of anti-Gal IgG, IgA, and IgM and anti-PCP IgG and IgG2 were determined in 59 CLL patients, 30 CVID patients, and 67 healthy controls. Levels of IgG, IgA, IgM, anti-Gal IgA, anti-Gal IgM, and anti-PCP IgA were lower in CLL and CVID patients than in healthy controls (p value for all parameters < 0.0001). Decrease in the levels of IgA, IgM, anti-Gal IgA, and anti-PCP IgA was less pronounced in the CLL group than in the CVID group. IgA decline, anti-Gal IgA, anti-PCP IgA, and anti-PCP IgG2 were negatively correlated with CLL stage. We devise the evaluation of anti-Gal antibodies to be a routine test in humoral immunodeficiency diagnostics, even in cases of immunoglobulin substitution therapy. Significant reductions, mainly in anti-Gal IgA, IgM, and anti-PCP IgA levels, may have prognostic importance in CLL patients.

Highlights

B cell lymphocytic leukaemia (CLL) is the most common leukaemia in western European adults [1]
In the CLL group, we observed a decrease below the normal range for age in at least one of the immunoglobulin classes in 38/59 (64.4%) CLL patients: IgG < 7.3 g/L in 18/59 (30.5%) patients; IgA < 0.8 g/L in 27/59 (45.7%) patients; and IgM < 0.4 g/L 28/59 (47.5%) patients
We present here the first report of a cohort of 30 common variable immunodeficiency (CVID) patients treated with immunoglobulin substitution therapy and 59 CLL nonsubstituted patients with confirmed decrease in anti-Gal IgA and IgM

Summary

Introduction

B cell lymphocytic leukaemia (CLL) is the most common leukaemia in western European adults [1]. Infectious complications are the major cause of morbidity and mortality in more than 50% of all Journal of Immunology Research

Objectives

Methods

Results

Conclusion